Mihajlović G
Federal Institut of Public Health, Belgrade.
Srp Arh Celok Lek. 1996 Jan-Feb;124(1-2):44-6.
Metamizole sodium (noraminophenazon sodium) is a pyrazolone derivate with analgesic, antipyretic and antiinflammatory activity, introduced in therapy in 1921. Since then, it was widely used all over the world, even in the counter preparations. In seventies its use was connected with severe, sometimes fatal side effects (agranulocytosis), resulting in gradual withdrawal of the drug. Metamizol has been withdrawn from the market in many developed countries, its use severely restricted in some of them, or permitted only in parenteral preparations for strictly defined indications (exceptionally severe pain such as posttraumatic, postoperative, abdominal colics and high body temperature unresponsive to the other antipyretics. In contrast to that, preparations containing metamizole are still in use in many countries, in some even as over the counter drugs.
安乃近（诺米那宗钠）是一种具有镇痛、解热和抗炎活性的吡唑啉酮衍生物，于1921年被引入治疗。从那时起，它在全世界广泛使用，甚至在非处方制剂中也有使用。在20世纪70年代，其使用与严重的、有时甚至致命的副作用（粒细胞缺乏症）相关联，导致该药物逐渐被停用。在许多发达国家，安乃近已退出市场，在一些国家其使用受到严格限制，或者仅允许用于有严格限定适应症的注射制剂（如创伤后、术后、腹部绞痛等异常严重的疼痛以及对其他退烧药无反应的高热）。与此形成对比的是，含有安乃近的制剂在许多国家仍在使用，在一些国家甚至作为非处方药使用。
